Related Experiment Video

Updated: Jan 7, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.1K

Clinical application of Azithromycin in treating pediatric Mycoplasma Pneumonia and its effects on platelet count,

Kun Dong1, Wenjuan Tong2, Songjian Lu3

  • 1Kun Dong, Department of Clinical Immunology, Anhui Children's Hospital, Hefei 233000, Anhui, China.

Pakistan Journal of Medical Sciences
|December 26, 2025
PubMed
Abstract

Insights

Azithromycin significantly improves treatment outcomes for pediatric mycoplasma pneumonia, leading to faster symptom relief and fewer adverse reactions compared to erythromycin.

Area of Science:

  • Pediatric Infectious Diseases
  • Respiratory Medicine
  • Pharmacology

Background:

  • Mycoplasma pneumonia is a common respiratory infection in children.
  • Current treatments have varying efficacy and side effect profiles.
  • Understanding optimal antibiotic strategies is crucial for pediatric care.

Purpose of the Study:

  • To evaluate the clinical effectiveness of azithromycin in treating pediatric mycoplasma pneumonia.
  • To assess azithromycin's impact on platelet count, D-dimer levels, and inflammatory markers.
  • To compare azithromycin with erythromycin in terms of efficacy and safety.

Main Methods:

  • Retrospective study of 80 children with mycoplasma pneumonia.
  • Two groups: azithromycin (observation, n=40) and erythromycin (control, n=40).
  • Comparison of clinical efficacy, symptom resolution time, laboratory markers, and adverse reactions.

Main Results:

  • Azithromycin group showed a significantly higher overall response rate (95%) than the erythromycin group (72.5%).
  • Faster resolution of fever, cough, and shorter hospitalization were observed with azithromycin.
  • Azithromycin significantly reduced platelet count, D-dimer, and inflammatory markers (TNF-α, CRP, IL-6) with fewer adverse reactions.

Conclusions:

  • Azithromycin is more effective than erythromycin for pediatric mycoplasma pneumonia.
  • It offers rapid symptom resolution, anti-inflammatory benefits, and improves coagulation balance.
  • Azithromycin presents a favorable safety profile for treating this condition in children.
Keywords:
AzithromycinD-dimerInflammatory factorsPediatric mycoplasma pneumoniaPlatelet count

More Related Videos

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae06:04

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Published on: February 24, 2023

2.8K
High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity09:09

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

Published on: November 16, 2016

8.3K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
191
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
155
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171